Radiation protection and mitigation potential of phenylbutyrate: delivered via oral administration

References

• Benzie IF, Strain JJ. 1996. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. 239:70–76.
   PubMed Web of Science ®Google Scholar
• Brown SL, Kolozsvary A, Liu J, Ryu S, Kim JH. 2008. Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat Res. 169:474–478.
   PubMed Web of Science ®Google Scholar
• Carducci MA, Gore S. 1997. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacological evaluation of intravenous and oral PB. Anticancer Res. 17:3972–3973.
   Google Scholar
• Chung YL, Wang AJ, Yao LF. 2004. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther. 3:317–325.
   PubMed Web of Science ®Google Scholar
• Chung YL, Lee MY, Pui NN. 2009. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis. 30:1387–1397.
   PubMed Web of Science ®Google Scholar
• Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A. 2000. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res. 6:4334–4342.
   PubMed Web of Science ®Google Scholar
• DiGiuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, Gore SD. 1999. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia. 8:1243–1253.
   Web of Science ®Google Scholar
• Dover GJ, Brusilow S, Charache S. 1994. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 84:339–343.
   PubMed Web of Science ®Google Scholar
• Epperly M, Jin SQ, Nie S, Cao S, Zhang X, Franciola D, Wang H, Fink M, Greenberger JS. 2007. Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation. Radiat Res. 168:552–559.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Filippini P, Ferlini C, Maggiano N, Stoler AB, Fruscella E, Mozzetti S, Mancuso S, Freedman RS, Scambia G, et al. 2000. Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells. Oncol Res. 12:429–440.
   PubMed Web of Science ®Google Scholar
• Fibach E, Prasanna P, Rodgers GP, Samid D. 1993. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood. 82:2203–2209.
   PubMed Web of Science ®Google Scholar
• Gore SD, Samid D, Weng LJ. 1997. Clinical development of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies. Anticancer Res. 17:3981–3982.
   Google Scholar
• Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, et al. 2002. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 8:963–970.
   PubMed Web of Science ®Google Scholar
• Hafer N, Maidment BW, Hatchett RJ. 2010. The NIAID Radiation Countermeasures Program business model. Biosecur Bioterror. 8:357–363.
   PubMedGoogle Scholar
• Haydont V, Bourgier C, Pocard M, Lusinchi A, Aigueperse J, Mathé D, Bourhis J, Vozenin-Brotons MC. 2007. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res. 13:5331–5334.
   PubMed Web of Science ®Google Scholar
• Hudgins WR, Fibach E, Safaya S, Rieder RF, Miller AC, Samid D. 1996. Transcriptional upregulation of gamma-globin by phenylbutyrate and analogous aromatic fatty acids. Biochem Pharmacol. 52:1227–1233.
   PubMed Web of Science ®Google Scholar
• Jung M. 2001. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem. 8:1505–1511.
   PubMed Web of Science ®Google Scholar
• Katzung BG. 2009. Basic and clinical pharmacology, 11th ed. New York, NY: McGraw-Hill.
   Google Scholar
• Końca K, Lankoff A, Banasik A, Lisowska H, Kuszewski T, Góźdź S, Koza Z, Wojcik A. 2003. A cross platform public domain PC-image analysis program for the comet assay. Mutat Res. 10:15–20.
   Web of Science ®Google Scholar
• Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. 2006. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res. 12:5199–5206.
   PubMed Web of Science ®Google Scholar
• Massague J, Blain SW, Lo RS. 2001. TGFh signaling in growth control, cancer, and heritable disorders. Cell. 103:295–309.
   Web of Science ®Google Scholar
• Miller AC, Cohen S, Stewart M, Rivas R, Lison P. 2011. Radioprotection by the histone deacetylase inhibitor phenylbutyrate. Radiat Environ Biophys. 50:585–596.
   PubMed Web of Science ®Google Scholar
• Miller AC, Whittaker T, Thibault A, Samid D. 1997. Modulation of radiation response of human tumor cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int J Radiat Biol. 72:211–218.
   PubMed Web of Science ®Google Scholar
• Miller AC, Samid D. 1997. Modification of radiation response based on the use of inhibitors of the mevalonate pathway of cholesterol synthesis. Adv Exp Med Biol. 400B:825–830.
   PubMed Web of Science ®Google Scholar
• Miller AC, Whittaker T, Page N. 2001. Suppression of depleted uranium-induced neoplastic transformation of human cells by the phenyl fatty acid, phenyl acetate: chemoprevention by targeting the p21RAS protein pathway. Radiat Res. 155:163–170.
   PubMed Web of Science ®Google Scholar
• Nübel T, Damrot J, Roos W, Kaina B, Fritz G. 2006. Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res. 2:933–939.
   Web of Science ®Google Scholar
• Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, Perrine SP. 2002. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood. 100:4640–4648.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Figg WD. 2004. Histone deacetylase inhibitors are potent radiation protectants. Cancer Biol Ther. 3:612–613.
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA. 2005. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol. 7:177–182.
   PubMed Web of Science ®Google Scholar
• Prasanna P, Thibault A, Liu L, Samid D. 1996. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem. 66:710–716.
   PubMed Web of Science ®Google Scholar
• Rael LT, Thomas GW, Craun ML, Curtis CG, Bar-Or R, Bar-Or D. 2007. Lipid peroxidation and the thiobarbituric acid assay: standardization of the assay when using saturated and unsaturated fatty acids. J Biochem Mol Biol. 37:749–752.
   Google Scholar
• Resar LM, Segal JB, Fitzpatrick LK, Friedmann A, Brusilow SW, Dover GJ. 2002. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol. 9:737–741.
   Web of Science ®Google Scholar
• Samid D, Shack S, Sherman LT. 1992. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res. 52:1988–1992.
   PubMed Web of Science ®Google Scholar
• Samid D, Shack S, Myers CE. 1993. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest. 91:2288–2295.
   PubMed Web of Science ®Google Scholar
• Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE. 1997. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Advances. Experimental. Med Biol. 400A:501–505.
   Google Scholar
• Samid D, Wells M, Greene ME, Shen W, Palmer CN, Thibault A. 2000. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res. 6:933–941.
   PubMed Web of Science ®Google Scholar
• Seed TM. 2002. New strategies for the prevention of radiation injury. JRR. 43:S239–S244.
   PubMed Web of Science ®Google Scholar
• Seed TM. 2005. Radiation protectants: current status and future prospects. Health Phys. 89:531–545.
   PubMed Web of Science ®Google Scholar
• Singh VK, Brown DS, Kao TC. 2010. Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocyte-colony stimulating factor. Int J Radiat Oncol Biol. 86:12–21.
   Web of Science ®Google Scholar
• Rahman L, Kode A, Biswas SK. 2007. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 1:3159–3165.
   Web of Science ®Google Scholar
• Thibault A, Figg WD, Samid D. 1996. A Phase I study of the differentiating agent phenylbutyrate in patients with cancer. Proceedings Annual Meeting American Society Clinical Oncology 15:A1539.
   Google Scholar
• Wang J, Boerma M, Fu Q, Kulkarni A, Fink LM, Hauer-Jensen M. 2007. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys. 68:1483–1490.
   PubMed Web of Science ®Google Scholar
• Weiss JF, Landauer MR, Hogan JB, Gunter-Smith PJ, Benson KA, Neta R, Hanson WR. 1997. Modification of radiation-induced gastrointestinal and hematopoietic injury in mice by combinations of agents: effects of indomethacin and caffeine. Adv Exp Med Biol. 400B:865–872.
   PubMed Web of Science ®Google Scholar
• Whitnall MH, Inal CE, Jackson WE, Miner VL, Villmar V, Seed TM. 2001. In vivo radioprotection against gamma-irradiation with 5-androstendiol: stimulation of the innate immune system. Radiat Res. 156:283–293.
   PubMed Web of Science ®Google Scholar
• Wieser R. 2002. The transforming growth factor signaling pathway in tumorigenesis. Curr Opin Oncol. 13:70–77.
   Web of Science ®Google Scholar
• Wojewódzka M, Kruszewski M, Buraczewska I, Xu W, Massuda E, Zhang J, Szumiel I. 2007. Sirtuin inhibition increases the rate of non-homologous end-joining of DNA double strand breaks. Acta Biochim Polish 54:63–69.
   PubMed Web of Science ®Google Scholar